No profile data available.
Insmed Incorporated (INSM) is a healthcare company in the antibacterial pharmaceuticals industry, based in Bridgewater, United States, with about 1,664 full-time employees.
It reported revenue of $606.42 million for fiscal year 2025, up 66.7% from fiscal year 2024, and net income of -$1.28 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $425.49 million, up 296.1% from a year before. United States was its largest region in fiscal year 2025, with 75% of revenue. Its market capitalization was $21.97 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Insmed reported $606.42 million in revenue for fiscal year 2025, up 66.7% from $363.71 million in fiscal year 2024. In Q2 2026 revenue was $425.49 million.
United States: 75% of revenue by region in fiscal year 2025, followed by International (25%).
$21.97 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (antibacterial pharmaceuticals) include Vaxcyte, Inc. (PCVX), AN2 Therapeutics, Inc. (ANTX), BGM Group Ltd. (BGM), Armata Pharmaceuticals, Inc. (ARMP).